Josh Ginsburg
Biotech, gold, insider ownership, natural resources

Advanced Cell Technology: Investors Should Consider Selling

Of all the company's which have managed to generate a large cult like following, perhaps no micro-cap stock has done as good of a job as the .07 cent stem cell company Advanced Cell Technology (ACTC.OB). Since the company's inception in the mid 90's as an animal cloning company, Advanced Cell Technology has managed to dilute its current number of outstanding shares to a whopping 2,560,000,000 since its original IPO. Needless to say, it has not been a profitable ride for long-term shareholders thus far. Rather, it appears that shareholders have been hit time and time again with dilutions, and questionable actions by management, which whether purposeful or accidental, has not reflected well on the company. Interestingly enough however, Advanced...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details